ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
February 07 2024 - 4:54PM
Business Wire
Reduction in intestinal damage enables
poultry farms to optimize feed utilization
Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a
biotech/agtech R&D company engaged in the development of
therapeutic, medicinal and nutritional product candidates derived
from proprietary algal cultures, announces additional findings from
its 42-day coccidiosis challenge study that demonstrate the
product’s positive impact on the cost of broiler production as an
alternative to commonly-used antibiotics.
ZIVO’s product candidate for use in poultry feed is designed to
boost immune response, allowing birds to effectively combat
coccidiosis and reduce the negative effects of the disease without
the use of antibiotics. These new results, along with earlier
findings, further demonstrate the benefits of ZIVO’s product across
the broiler production value chain.
ZIVO previously reported the effects of its product on the
health of broiler chickens exposed to coccidiosis during the course
of a 42-day grow out period, which is typical for the poultry
industry. These health benefits included a statistically
significant reduction in intestinal damage caused by the Eimeria
parasite compared with untreated control birds. This improvement in
intestinal health following parasite exposure was on par with the
market-leading commercial ionophore.
ZIVO now reports that this reduction in intestinal damage
enables poultry farms to optimize feed utilization as measured by
the Feed Conversion Ratio (FCR), which is the primary driver of
profitability. Similar to the outcomes related to intestinal
damage, ZIVO’s product resulted in a statistically significant
improvement in FCR compared with untreated controls. Further, these
results were not statistically different from the market-leading
commercial ionophore.
“We are confident that ZIVO’s product will offer poultry
producers a novel tool to accelerate the development of the immune
system in young birds, thereby mitigating the impact of coccidial
infection, reducing intestinal tissue damage and fostering overall
animal health and well-being to maximize profitability. As we
further analyze the results of our most recent 42-day challenge
study, we are finding that our coccidiosis treatment candidate
exhibits the potential to revolutionize the industry by achieving
significantly improved poultry outcomes at cost parity or better.
We believe these findings will facilitate and expand dialogues with
potential partners in the agriculture and animal health
industries,” said John Payne, Chairman and Chief Executive Officer
of ZIVO Bioscience.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight
loss, decreased performance and increased mortality in poultry.
This disease represents a significant economic challenge for the
global poultry industry, as indicated by a 2020 study that
estimated annual costs ranging from $10 billion to $17 billioni.
Products for treating coccidiosis are mostly antibiotic- or
ionophore-based, and no significant new commercial technology has
been introduced in the past 60 years. The global poultry industry
spends more than $1.5 billion annually on coccidiosis control,
primarily using decades-old compounds that industry and consumers
alike wish to replace due to the risks of developing drug
resistance. Coccidiosis is a common disease for chickens,
especially among young chicks, and can be fatal or result in
compromised digestion.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an
intellectual property portfolio comprised of proprietary algal and
bacterial strains, biologically active molecules and complexes,
production techniques, cultivation techniques and patented or
patent pending inventions for applications in human and animal
health. Please visit www.zivobioscience.com for more
information.
Forward Looking Statements
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, including with respect
to the Company’s product candidate’s potential to generate revenues
and the expected time frame for results of future studies. Words
such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements. Although
ZIVO believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our strategic partnerships may not facilitate
the commercialization or market acceptance of our products; risks
that we will be unable to increase production sufficient to meet
our expected demand; risks that our products may not be ready for
commercialization in a timely manner or at all; risks that our
products will not perform as expected based on results of our
pre-clinical and clinical trials; our ability to raise additional
funds; uncertainties inherent in the development process of our
products; changes in regulatory requirements or decisions of
regulatory authorities; the size and growth potential of the
markets for our products; the results of clinical trials, our
ability to protect our intellectual property rights and other
risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and ZIVO undertakes no
obligation to revise or update any forward–looking statements for
any reason, even if new information becomes available in the
future.
i Blake, D.P., Knox, J., Dehaeck, B. et al. Re-calculating the
cost of coccidiosis in chickens. Vet Res 51, 115 (2020).
https://doi.org/10.1186/s13567-020-00837-2
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240207487706/en/
ZIVO Bioscience Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130 kmarchiando@zivobioscience.com LHA Investor
Relations Tirth T. Patel (212) 201-6614 tpatel@lhai.com
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Oct 2023 to Oct 2024